Results 141 to 147 of about 2,910 (147)

[Efficacy and safety of tenofovir amibufenamide in the treatment of patients over 65 years of age with chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Chu SS, Liu X, Xu C, Qiu GZ, Xu Y, Deng J, Fu ML, Peng YL, Gao F.   +8 more
europepmc   +1 more source

[Revealing research progress for immunological characteristics of chronic hepatitis B applying single-cell RNA sequencing technology]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Shu C, Zhang DZ.
europepmc   +1 more source

[Real-world data of tenofovir amibufenamide therapy for treatment-naïve patients with chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Zheng JR, Feng B, Xie YD.
europepmc   +1 more source

[Exploring the reasons for liver cancer occurrence still after long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Liu X, Du XY, Lu FM.
europepmc   +1 more source

[Tenofovir amibufenamide combined with pegylated interferon α-2b in treatment of chronic hepatitis B patients with low-level viremia: a case report]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
He DX, Ma SL.
europepmc   +1 more source

[New progress on diagnosis and treatment for indeterminate-phase chronic hepatitis B virus-infected patients]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Liu JC, Wu C, Li J.
europepmc   +1 more source

[Long-term therapeutic outcomes of antiviral treatment in patients with chronic hepatitis B infection with normal alanine aminotransferase, mild liver inflammation, and fibrosis]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Shi YC, Tan YW.
europepmc   +1 more source